Literature DB >> 19124952

Risk of second primary cancer following prostate cancer radiotherapy: DVH analysis using the competitive risk model.

R Takam1, E Bezak, E E Yeoh.   

Abstract

This study aimed to estimate the risk of developing second primary cancer (SPC) corresponding to various radiation treatment techniques for prostate cancer. Estimation of SPC was done by analysing differential dose-volume histograms (DDVH) of normal tissues such as rectum, bladder and urethra with the competitive risk model. Differential DVHs were obtained from treatment planning systems for external beam radiotherapy (EBRT), low-dose-rate (LDR) and high-dose-rate (HDR) brachytherapy techniques. The average risk of developing SPC was no greater than 0.6% for all treatment techniques but was lower with either LDR or HDR brachytherapy alone compared with any EBRT technique. For LDR and HDR brachytherapy alone, the risk of SPC for the rectum was 2.0 x 10(-4)% and 8.3 x 10(-5)% respectively compared with 0.2% for EBRT using five-field 3D-CRT to a total dose of 74 Gy. Overall, the risk of developing SPC for urethra following all radiation treatment techniques was very low compared with the rectum and bladder. Treatment plans which deliver equivalent doses of around 3-5 Gy to normal tissues were associated with higher risks of development of SPC.

Entities:  

Mesh:

Year:  2009        PMID: 19124952     DOI: 10.1088/0031-9155/54/3/009

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  6 in total

Review 1.  High dose rate prostate brachytherapy: an overview of the rationale, experience and emerging applications in the treatment of prostate cancer.

Authors:  A Challapalli; E Jones; C Harvey; G O Hellawell; S A Mangar
Journal:  Br J Radiol       Date:  2012-11       Impact factor: 3.039

2.  A dosimetric selectivity intercomparison of HDR brachytherapy, IMRT and helical tomotherapy in prostate cancer radiotherapy.

Authors:  Johanne Hermesse; Sylvie Biver; Nicolas Jansen; Eric Lenaerts; Nathalie De Patoul; Stefaan Vynckier; Philippe Coucke; Pierre Scalliet; Philippe Nickers
Journal:  Strahlenther Onkol       Date:  2009-11-10       Impact factor: 3.621

3.  In silico nanodosimetry: new insights into nontargeted biological responses to radiation.

Authors:  Zdenka Kuncic; Hilary L Byrne; Aimee L McNamara; Susanna Guatelli; Westa Domanova; Sébastien Incerti
Journal:  Comput Math Methods Med       Date:  2012-06-03       Impact factor: 2.238

Review 4.  Second primary cancers after radiation for prostate cancer: a review of data from planning studies.

Authors:  Louise Murray; Ann Henry; Peter Hoskin; Frank-Andre Siebert; Jack Venselaar
Journal:  Radiat Oncol       Date:  2013-07-08       Impact factor: 3.481

Review 5.  Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis.

Authors:  Christopher J D Wallis; Alyson L Mahar; Richard Choo; Sender Herschorn; Ronald T Kodama; Prakesh S Shah; Cyril Danjoux; Steven A Narod; Robert K Nam
Journal:  BMJ       Date:  2016-03-02

Review 6.  High prevalence of secondary bladder cancer in men on radiotherapy for prostate cancer: evidence from a meta-analysis.

Authors:  Shankun Zhao; Qiang Xie; Redian Yang; Jiamin Wang; Chaofeng Zhang; Lianmin Luo; Zhiguo Zhu; Yangzhou Liu; Ermao Li; Zhigang Zhao
Journal:  Cancer Manag Res       Date:  2019-01-10       Impact factor: 3.989

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.